Zymeworks (ZYME) Enterprise Value (2021 - 2026)
Zymeworks (ZYME) posted Enterprise Value of -$364.7 million for Q1 2026, down 59.41% sequentially from -$228.8 million in Q4 2025, and down 37.48% YoY from -$583.4 million in Q1 2025.
Zymeworks (ZYME) Enterprise Value (2021 - 2026) Analysis & Trends
Zymeworks has reported Enterprise Value for 6 years, with the latest figure at -$364.7 million in Q1 2026.
- Quarterly Enterprise Value fell 37.48% year-over-year to -$364.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$364.7 million (down 37.48% YoY) and the FY2025 annual result came in at -$228.8 million, down 1.34% from the prior year.
- Enterprise Value eased to -$364.7 million in Q1 2026 per ZYME's latest filing, from -$228.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$166.2 million in Q3 2022 and troughed at -$492.2 million in Q4 2022.
- A 5-year average of -$306.6 million and a median of -$297.2 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2024: Enterprise Value plunged 94.86% in 2022, then jumped 39.68% in 2024.
- Over 5 years, Enterprise Value stood at -$492.2 million in 2022, then climbed by 23.95% to -$374.3 million in 2023, then soared by 39.68% to -$225.8 million in 2024, then retreated by 1.34% to -$228.8 million in 2025, then plunged by 59.41% to -$364.7 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$364.7 million, -$228.8 million, and -$251.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Zymeworks | 1.79 Bn | 1.52 Bn | - | -270.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -270.70 Mn |
| Mar 31, 2026 | -364.73 Mn |
| Dec 31, 2025 | -228.80 Mn |
| Sep 30, 2025 | -251.93 Mn |
| Jun 30, 2025 | -281.38 Mn |
| Mar 31, 2025 | -265.29 Mn |
| Dec 31, 2024 | -225.78 Mn |
| Sep 30, 2024 | -297.20 Mn |
| Jun 30, 2024 | -330.15 Mn |
| Mar 31, 2024 | -345.05 Mn |
| Dec 31, 2023 | -374.33 Mn |
| Sep 30, 2023 | -295.41 Mn |
| Jun 30, 2023 | -340.09 Mn |
| Mar 31, 2023 | -340.79 Mn |
| Dec 31, 2022 | -492.23 Mn |
| Sep 30, 2022 | -166.24 Mn |
| Dec 31, 2021 | -252.61 Mn |